StoryResearch
Sana announces SC451 IND filing planned for 2026 and strategic collaboration with Mayo Clinic
Sana Biotechnology announced plans to file an Investigational New Drug application for SC451, its iPSC-derived pancreatic islet cell therapy, as early as 2026, with phase 1 clinical trial initiation expected the same year. The company also entered a strategic collaboration with Mayo Clinic to accelerate SC451 development and standardize transplant delivery.
- SC451 is an O-negative, HIP-modified, iPSC-derived pancreatic islet cell therapy
- Uses same hypoimmune platform technology as UP421 clinical trial
- FDA INTERACT meeting completed; confidence increased in manufacturing and testing plans
- Partnership with Mayo Clinic will accelerate development, standardization, and patient access
- First-in-human proof-of-concept data expected within 12–18 months